ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3135

Influence of Baseline Magnetic Resonance Imaging Features on Outcomes of Operative and Non-Operative Treatment of Meniscal Tear in Patients ≥ 45

Lindsey MacFarlane1, Heidi Y. Yang2, Jamie E. Collins3,4, Ali Guermazi5, Morgan Jones6, Amelia Winter2, Elena Losina4,7 and Jeffrey N. Katz4,8, 1Rheumatology, Brigham & Women's Hospital, Boston, MA, 2Orthopaedic and Arthritis Center for Outcomes Research, Brigham & Women's Hospital, Boston, MA, 3Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham & Women's Hospital, Boston, MA, 4Harvard Medical School, Boston, MA, 5Boston University School of Medicine, Boston, MA, 6Orthopedic Surgery, Cleveland Clinic, Cleveland, OH, 7Orthopaedics, Brigham & Women's Hospital, Boston, MA, 8Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: meniscectomy, osteoarthritis and outcomes

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 16, 2016

Title: Osteoarthritis – Clinical Aspect II: Treatment and Imaging

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: In the treatment of meniscal damage in the setting of mild to moderate osteoarthritis (OA), several randomized trials found that both arthroscopic partial meniscectomy (APM) and physical therapy (PT) led to substantial pain relief. Whether certain subgroups of patients have worse outcomes with APM vs. PT is unknown. We hypothesize that increased baseline cartilage damage and presence of bone marrow lesions (BML) on magnetic resonance imaging (MRI) modifies the efficacy of APM compared to PT.

Methods: We used the data from the Meniscal Tear in Osteoarthritis Research (MeTeOR) Trial of APM vs. PT. Subjects were ≥45 years old and had meniscal damage on MRI, evidence of OA changes on imaging, and knee symptoms. Patients who were randomized to APM generally had surgery within three weeks after randomization. Patients who crossed-over between treatment groups were excluded from this analysis.  MRIs were read using the MRI OA Knee Score (MOAKS). All 15 subregions were analyzed. Maximum, cartilage damage in any subregion (% of loss that is full thickness) was dichotomized at <10% vs. ≥10% and maximum BML in any subregion (% of subregion occupied) at none vs. any. The outcome was change from baseline to 6 months in the Knee Injury and Osteoarthritis Outcome Pain Score (KOOS, scored 0-100, 100 worst). We investigated the interaction between the imaging variables (cartilage damage, BML), treatment type (APM, PT) and change in KOOS Pain. We then calculated the difference in mean change between those receiving APM and PT for each imaging category.

Results: The sample consisted of 223 knees (one per person); 129 (58%) had APM and 94 (42%) PT. The baseline KOOS Pain in all imaging categories ranged from 44-45 points. Patients with ≥10% cartilage damage had similar improvement in pain with PT and APM (23 points), while patients with <10% cartilage damage had greater improvement with APM than with PT (28 vs 20 points). Those with BML also had similar improvement with APM and PT (24 vs 23 points), while those with no BMLs had greater improvement with APM than with PT (29 vs 16 points). While these difference in efficacy of APM vs. PT were clinically relevant (MCID~8 points) they did not reach statistical significance. (p-value for interaction =0.17 for cartilage damage and 0.11 for BML).

Conclusion: These data suggest that for patients with more extensive baseline cartilage damage and BMLs there is no clinically meaningful difference in pain outcomes between management with APM vs. PT. However, though not statistically significant, our data suggest that patients with less cartilage damage and those with no BMLs at baseline may receive more symptomatic benefit from APM than from PT. These relationships should be pursued in larger cohorts to further assess the role of APM in management of meniscal tear in those with less cartilage damage or no BMLs.  

Table 1 

 

N (%)

Baseline

KOOS Pain, mean (SE)

ΔKOOS Pain (95% CI) at 6 months

APM

PT

P interaction

Cartilage Damage        

 

≥10%

151 (68)

45.8 (16.1)

-23.2

(-27.2,-19.4)

-23.1

(-27.5, -18.7)

0.17

 

<10%

69 (31)

44.4 (16.0)

-27.9

(-33.5,-22.4)

-20.3

(-27.2, -13.4)

Bone Marrow lesion

 

 

 

 

 

Any

185 (85)

45.3 (16.6)

-23.9

(-27.5,-20.4)

-22.9

(-26.9,-18.9)

0.11

None

33 (15)

45.9 (13.1)

-28.8

(-36.5,-21.2)

-15.7

(-27.4, -4.0)

KOOS; Knee Injury and Osteoarthritis Outcome Score, SE; standard error, APM; arthroscopic partial meniscectomy, PT; physical therapy

Difference between APM and PT for change in KOOS Pain at 6 months for each imaging category with confidence intervals  


Disclosure: L. MacFarlane, None; H. Y. Yang, None; J. E. Collins, None; A. Guermazi, MerckSerono, TissueGene, OrthoTrophix, AstraZeneca, Genzyme, 5,Boston Imaging Core Lab, LLC, 1; M. Jones, None; A. Winter, None; E. Losina, None; J. N. Katz, None.

To cite this abstract in AMA style:

MacFarlane L, Yang HY, Collins JE, Guermazi A, Jones M, Winter A, Losina E, Katz JN. Influence of Baseline Magnetic Resonance Imaging Features on Outcomes of Operative and Non-Operative Treatment of Meniscal Tear in Patients ≥ 45 [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/influence-of-baseline-magnetic-resonance-imaging-features-on-outcomes-of-operative-and-non-operative-treatment-of-meniscal-tear-in-patients-%e2%89%a5-45/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/influence-of-baseline-magnetic-resonance-imaging-features-on-outcomes-of-operative-and-non-operative-treatment-of-meniscal-tear-in-patients-%e2%89%a5-45/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology